[Multiorgan resection in combination with intraoperative, hyperthermic chemotherapy in recurrent fibrolamellar hepatocellular carcinoma. An individual therapeutic concept for a 21-year-old patient].
The fibrolamellar karzinoma of the liver (FLC) as an uncommon variant of the hepatocellular karzinoma (HCC) is an indolent growing tumor. In its prior manifestation the FLC occurs at the adolescence and young adult stage. Early stage diagnosis and aggressive surgical treatment achieve better long-term results than usual resection of the HCC. Usually the FLC is, caused by its inconspicuous clinical appearance, diagnosed at a stage too advanced for effective surgical treatment. Especially the young patient's age and the remaining therapeutic options for palliative or curative treatment postulate a difficult decision for the surgeon. When a subtotal hepatectomy cannot be performed, total hepatectomy with liver transplantation is a valuable option. Palliative treatment protocols include systemic chemotherapy, ethanol instillation and chemoembolisation. We report the case of a 21-year-old male patient who presented with a recurrent intrahepatic FLC, peritoneal karzinomatosis confined to the right lower abdomen including gastric, splenic, diaphragmatic and colon transversum metastasis 14 months after primary surgery. We selected this patient as a reasonable candidate for an extended resection in trying to offer the optimal therapeutic modality. Thus we performed a right hemihepatectomy, near complete resection of the right diaphragm, total gastrectomy with lymphadenectomy including en bloc resection of spleen, colon transversum, omentum majus and peritonectomy of the paravesical region. Furthermore hyperthermic intraperitoneal chemotherapy was carried out the next day. The patient's postoperative course remained uncomplicated with fast recovery. Presently, 6 months after surgery, the patient has no evidence of recurrence.
Braune
C
C
Orthopädische Universitätsklinik und Poliklinik, Friedrichsheim Frankfurt/Main. C.Braune@em.uni-frankfurt.de
Fangmann
J
J
Scheumann
G F
GF
Klempnauer
J
J
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000601:surgery*; D002945:Cisplatin / Q000008:administration & dosage*; D003082:Colectomy; D003110:Colonic Neoplasms / Q000556:secondary / Q000601:surgery; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D005743:Gastrectomy; D006498:Hepatectomy; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D008197:Lymph Node Excision; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000601:surgery*; D009852:Omentum / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000601:surgery; D010537:Peritoneum / Q000601:surgery; D011182:Postoperative Care; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000556:secondary / Q000601:surgery; D013274:Stomach Neoplasms / Q000556:secondary / Q000601:surgery; D013997:Time Factors
D000970:Antineoplastic Agents; D002945:Cisplatin